MEK1/2与ATR联合抑制通过STAT3依赖机制在体外和体内促进骨髓瘤细胞死亡
研究探讨MEK1/2抑制剂增强ATR拮抗剂抗骨髓瘤活性的机制。ATR抑制剂BAY1895344与MEK1/2抑制剂如cobimetinib联用协同增加多种骨髓瘤细胞系死亡,机制为分别阻断STAT3 Tyr705和Ser727磷酸化,导致STAT3失活及下游靶点c-Myc和BCL-XL下调。该方案对原代CD138+骨髓瘤细胞有活性而对正常CD34+细胞无活性,并在骨髓瘤异种移植模型中显著改善生存且毒性极小。
要点
- BAY1895344与cobimetinib协同增加骨髓瘤细胞死亡,并阻断STAT3 Tyr705和Ser727磷酸化。
- 该方案对硼替佐米高度耐药细胞和原代CD138+骨髓瘤细胞有活性,对正常CD34+细胞无活性。
- ATR抑制剂/cobimetinib方案在骨髓瘤异种移植模型中显著改善生存,毒性极小。
核心结论
- 联合ATR/MEK1/2抑制触发STAT3 Tyr705和Ser727双重去磷酸化、细胞保护性靶点显著下调和骨髓瘤细胞死亡,值得作为骨髓瘤新型治疗策略关注。
研究设计与样本
- 体外研究采用多种骨髓瘤细胞系、硼替佐米高度耐药(PS-R)细胞、患者来源条件培养基及原代CD138+骨髓瘤细胞与正常CD34+细胞。
- 体内研究采用骨髓瘤异种移植模型,包括硼替佐米耐药模型。
主要发现
- BAY1895344与cobimetinib联用协同增加多种骨髓瘤细胞系细胞死亡。
- BAY和cobimetinib分别阻断STAT3 Tyr705和Ser727磷酸化,双重去磷酸化触发STAT3显著失活及下游靶点c-Myc和BCL-XL下调。
- 在硼替佐米高度耐药(PS-R)细胞、患者来源条件培养基存在下以及使用替代ATR抑制剂(如M1774)和MEK1/2抑制剂(trametinib)时出现类似事件。
- 组成性活性STAT3、c-MYC或BCL-XL异位表达显著保护细胞免受BAY/cobimetinib作用;转染显性负性STAT3(Y705F)或ATR shRNA敲低使细胞对cobimetinib敏感;MEK1/2敲低显著增加ATRi敏感性。
- BAY/cobimetinib方案对原代CD138+骨髓瘤细胞有活性,但对正常CD34+细胞无活性;在骨髓瘤异种移植模型(包括硼替佐米耐药模型)中显著改善生存,毒性极小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mechanisms underlying potentiation of the anti-myeloma (MM) activity of ataxia telangiectasia Rad3 (ATR) antagonists by MAPK (Mitogen-activated protein kinases)-related extracellular kinase 1/2 (MEK1/2) inhibitors were investigated. Co-administration of the ATR inhibitor (ATRi) BAY1895344 (BAY) and MEK1/2 inhibitors, for example, cobimetinib, synergistically increased cell death in diverse MM cell lines. Mechanistically, BAY and cobimetinib blocked STAT3 Tyr705 and Ser727 phosphorylation, respectively, and dual dephosphorylation triggered marked STAT3 inactivation and downregulation of STAT3 (Signal transducer and activator of transcription 3) downstream targets (c-Myc and BCL-XL). Similar events occurred in highly bortezomib-resistant (PS-R) cells, in the presence of patient-derived conditioned medium, and with alternative ATR (e.g. M1774) and MEK1/2 (trametinib) inhibitors. Notably, constitutively active STAT3 c-MYC or BCL-XL ectopic expression significantly protected cells from BAY/cobimetinib. In contrast, transfection of cells with a dominant-negative form of STAT3 (Y705F) sensitized cells to cobimetinib, as did ATR shRNA knockdown. Conversely, MEK1/2 knockdown markedly increased ATRi sensitivity. The BAY/cobimetinib regimen was also active against primary CD138+ MM cells, but not normal CD34+ cells. Finally, the ATR inhibitor/cobimetinib regimen significantly improved survival in MM xenografts, including bortezomib-resistant models, with minimal toxicity. Collectively, these findings suggest that combined ATR/MEK1/2 inhibition triggers dual STAT3 Tyr705 and Ser727 dephosphorylation, pronounced downregulation of cytoprotective targets and MM cell death, warranting attention as a novel therapeutic strategy in MM.
引用
- Li L, Hu X, Nkwocha J, et al. Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivo. Br J Haematol. 2024. PMID: 39379134. doi:10.1111/bjh.19796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。